Breast Cancer Research

official impact factor 5.79

Email this article to a friend

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

David W Miles

Breast Cancer Research 2009, 11:208 doi:10.1186/bcr2237

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.